New Delhi: Hospital chain, Apollo Hospitals, has partnered with Belgium-based Ion Beam Applications ... Apollo Hospitals had introduced proton therapy at its cancer centre in Chennai and the ...

Apollo Hospitals on Tuesday said it has tied up with Ion Beam Applications to introduce proton beam therapy solutions for cancer treatment. The healthcare major has tied up with Ion Beam Applications ...

In collaboration with Hitachi, the National Cancer Centre Singapore has introduced Proton Beam Therapy - a treatment designed to target tumours with precision while reducing the impact on healthy ...

The company's pipeline has evolved significantly in recent years to keep up with demand, with newer cancer therapies making up a rising proportion of its plans for its roster of medicines.

Interventional therapies, including transarterial chemoembolization (TACE), yttrium-90 selective internal radiation therapy (90 Y SIRT), and ablation ... while CT lacks real-time imaging capabilities.

The most common type of radiation therapy used to treat breast cancer is external beam radiation. A specialized type of this, called proton therapy, targets just the tumor so the surrounding ...

If you have a cancer that can't be cured, your doctor may still suggest you use "palliative" radiation therapy. The goal is to shrink tumors and ease symptoms of your disease. External beam ...

aDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA bDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer ...

For people whose lymphoma has not responded to standard treatments, this innovative therapy could have a significant positive impact on their lives. For people living with this aggressive blood cancer ...

Cancer treatment has come a long way in recent years, offering patients more targeted and effective therapies with fewer side effects. One of the most advanced treatments available today is proton ...

Trends in inpatient outcomes of bladder cancer: 2008-2021. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a full text component.